Back HBV Disease Progression Transplant/Artificial Liver

Liver Transplant - HBV

Researchers Grow Liver Tissue from Pluripotent Stem Cells

Japanese researchers have produced liver-like tissue from induced pluripotent stem cells in the laboratory that can process drugs like a human liver, according to a presentation at the 10th annual meeting of the International Society for Stem Cell Research last week in Yokohama.alt

Read more:

Changes Proposed for Allocation of Donated Livers

For some patients transplantation is the only treatment for advanced liver disease due to chronic hepatitis B, hepatitis C, liver cancer, alcoholism, or other causes. But the supply of donor livers does not meet the demand, meaning that many people die while on a waiting list. As described in the September 2011 issue of Liver Transplantation, experts have been meeting for the past 2 years to develop a modified allocation system that aims to reduce wait-list mortality.

Read more:

EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival

An out-of-body liver dialysis device known as the Molecular Adsorbents Recirculating System (MARS) -- which takes over some lost filtering function in people with liver failure -- reduced levels of toxic substances in the blood and improved symptoms of hepatic encephalopathy in patients with acute-on-chronic liver failure, though it did not significantly extend survival, according to a late-breaker presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna. Another study found that the Prometheus extracorporeal liver support system also did not improve survival overall, though it did help specific groups of patients.

Read more:

Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease

An artificial liver device known as ELAD -- which runs a patient's blood through cartridges containing human liver cells -- conferred a significant survival advantage for people with acute decompensated liver disease related to chronic hepatitis B or C, according to a Chinese study presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. After 3 years, 44% of ELAD users were still alive without liver transplants, compared with 18% in the standard therapy group.

Read more:

Adefovir (Hepsera) Prevents Post-transplant HBV Recurrence as well as HBIG

Liver transplantation is the only treatment for end-stage liver failure due to chronic hepatitis B virus (HBV) infection, but without preventive therapy, the virus typically quickly attacks the new liver, which can lead to complications, organ failure, and death.

Read more: